Supported by WILLOW trial findings, the oral TLR 7/8 inhibitor demonstrated significant, dose-dependent reductions in skin disease activity for patients with lupus.

In the INTEGUMENT-INFANT trial, 34.4% of patients achieved vIGA-AD success and 58.3% reached EASI-75 at week 4.

Backed by phase 3 RINGSIDE data showing an 84% reduction in the risk of disease progression or death, the investigational agent moves ahead in the regulatory pipeline.

The US launch of Xtoro introduces a novel fluoroquinolone targeting key pathogens in acute otitis externa, delivering rapid ear pain cessation and high clinical cure rates.

Researchers found that 140 individuals (32.1%) reported lifetime GLP-1 RA use and 96 (22.0%) reported current use. HealthDay ...

Credit: Vera Therapeutics. Trutakna is supplied as a 150mg/mL single-dose prefilled autoinjector. Trutakna (atacicept-vymj), a first-in-class dual BAFF and APRIL inhibitor, secured FDA accelerated ...

New 26-week data from the phase 3 COMP006 study validate the long-term durability, safety, and remission potential of a 2-dose COMP360 psilocybin regimen for highly chronic, treatment-resistant ...

A Prescription Drug User Fee Act target date of November 1, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug ...

High-dose docosahexaenoic acid (DHA) supplementation does not yield a change in brain volume or cognitive performance over 24 months, according to a study publi ...

A PDUFA target date of April 24, 2027 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for ReNu ®, a ...

Those using upadacitinib had lower risk for discontinuing treatment, regardless of previous exposure to treatment ...